12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Varisolve polidocanol microfoam: Phase III started

BTG began a 6-month, double-blind, placebo-controlled, U.S. Phase III trial (Study VV017) to evaluate 0.5% or 1.0% Varisolve following endovenous thermal ablation in 105 patients. The company also withdrew a request...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >